Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicare Rx Formularies May Omit Lexapro Or Celexa, CMS Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Both antidepressants are not needed on Part D drug formularies “since escitalopram is the component of citalopram that is responsible for the antidepressant effects,” CMS says. Iressa and Cerebyx may also be left off formularies despite the requirement that “all or substantially all” drugs in their categories be included.

You may also be interested in...



Eisai's Rufinamide Estimated User Fee Deadline Is July 2006

The company submitted its NDA for the anti-epileptic on Sept. 9 for the orphan indication of adjunctive therapy for Lennox-Gastaut syndrome and for adjunctive therapy for partial-onset seizures.

Eisai's Rufinamide Estimated User Fee Deadline Is July 2006

The company submitted its NDA for the anti-epileptic on Sept. 9 for the orphan indication of adjunctive therapy for Lennox-Gastaut syndrome and for adjunctive therapy for partial-onset seizures.

Medicare Drug Plans Can Update Formularies Until Mid-September

Two-week window allows Part D plans to enhance or modify previously submitted formularies prior to the beginning of marketing activities.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134025

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel